Clinical Trial Outcomes

Find out about the results of our clinical research and get information on ongoing trials happening across the UK.

Completed trials

MUK one

A Phase II trial identifying the optimal dose of bendamustine when given in combination with thalidomide and dexamethasone in relapsed and/or refractory myeloma patients.

In partnership with: Napp Pharmaceuticals

Results

Publication in the British Journal of Haematology in 2015: “This study demonstrates bendamustine at 60 mg/m2 twice per month with thalidomide and dexamethasone is deliverable for repeated cycles in heavily pre-treated myeloma patients and has substantial clinical activity.”

What this means for patients

This study increased evidence this combination of drugs (bendamustine with thalidomide and dexamethasone) could benefit relapsed/refractory myeloma patients.

Data from this trial was also used to help inform on the successful NICE appraisal of another combination of drugs (pomalidomide with dexamethasone) for treating relapsed/refractory multiple myeloma, previously treated with lenalidomide and bortezomib. Get more details on this appraisal in this article.


MUK three

A Phase I/IIa trial identifying the optimal dose of CHR-3996 in combination with tosedostat for relapsed and/or refractory myeloma patients.

In partnership with: Chroma Therapeutics

Results

Final results being prepared for publication.


MUK four

A Phase II trial assessing the effectiveness of vorinostat in combination with bortezomib and dexamethasone (VVD) in relapsed and/or relapsed refractory myeloma patients.

In partnership with: Merck Sharp & Dohme Ltd

Results

Final results being prepared for publication.


MUK six

A Phase I/IIa trial of panobinostat in combination with Velcade, thalidomide and dexamethasone (VTD) for relapsed and/or refractory myeloma patients who have received between one to four previous lines of treatment.

In partnership with: Novartis

Results

Publication in the Publication in Lancet Haematology in 2016: “Panobinostat 20 mg in combination with bortezomib, thalidomide, and dexamethasone is an efficacious and well tolerated regimen for patients with relapsed multiple myeloma.”

What this means for patients

This study increased the evidence for using the drug panobinostat with bortezomib, thalidomide, and dexamethasone in relapsed/refractory myeloma patients.

Ongoing clinical trials – closed to recruitment

MUK five

A Phase II trial comparing the effectiveness of Kyprolis (carfilzomib), cyclophosphamide and dexamethasone (CCD) against cyclophosphamide, Velcade and dexamethasone (CVD) for myeloma patients at first relapse.

In partnership with: Onyx Pharmaceuticals / Amgen

Results

The first data analysis from this study was presented at the American Society of Hematology conference, December 2017 – an important annual meeting for blood cancer scientists and doctors to share their research findings: “Major response to KCD therapy is non-inferior to VCD and overall response rate is superior to VCD over a fixed treatment duration.”

There will be further publications of the trial data once complete.

What this means for patients

This study has increased the evidence for using a new triple combination of drugs – carfilzomib, cyclophosphamide and dexamethasone (CCD) instead of cyclophosphamide, Velcade and dexamethasone (CVD) – for patients at their first relapse.


MUK seven

A randomised Phase II trial comparing the triplet combination of pomalidomide, cyclophosphamide and dexamethasone against the standard combination of pomalidomide and dexamethasone in relapsed and/or refractory myeloma patients who have received at least two previous lines of treatment including both Revlimid and a proteasome inhibitor.

In partnership with: Celgene Ltd

Results

Initial findings of this study were presented at the American Society of Hematology conference, December 2017.

What this means for patients

This trial is looking at how to improve outcomes for patients based on their genetic biomarkers, predicting which patients would benefit from different drug combinations.

It will increase the evidence for the triple combination of pomalidomide, cyclophosphamide and dexamethasone in relapsed/refractory patients, and provide genetic biomarker data towards the identification (and stratification) of patients more or less likely to respond to this treatment.

Ongoing clinical trials – open to recruitment

MUK eight

A randomised Phase II trial comparing Ninlaro (ixazomib) in combination with cyclophosphamide and dexamethasone against cyclophosphamide and dexamethasone in relapsed and/or refractory myeloma patients who have previously had thalidomide, Velcade and Revlimid treatment.

In partnership with: Takeda Pharmaceutical Company Ltd

Results

None as yet, recruitment ongoing.

What this means for patients

Eligible patients who are taking part in the trial are accessing a new triple drug combination.


MUK nine, a stratified Phase II trial of two parts:
MUK nine a:

A screening protocol to identify newly diagnosed myeloma participants who are of ‘higher risk’ by genetic criteria.

MUK nine b:

A treatment protocol of patients with genetically-defined ‘higher risk’ patients from MUK nine a with a combination of bortezomib (Velcade), lenalidomide (Revlimid) dexamethasone, daratumumab (Darzalex) with cyclophosphamide.

In partnership with: Celgene Ltd, Janssen Pharmaceutica

Results

None as yet, recruitment ongoing.

To raise awareness of the study, an outline of the trial was presented at the American Society of Hematology conference, December 2017.

What this means for patients

If this trial is successful we’ll get more information about treating a challenging subtype of myeloma. This could then lead to a larger Phase III trial. It will also help us demonstrate how genetic screening from patient bone marrow can be used to identify and treat certain myeloma patients (known as stratified medicine).


MUK eleven

A Phase I Study to Assess the Safety and Tolerability of a Reovirus (Reolysin) in Combination with Lenalidomide and Pomalidomide in relapsed/refractory myeloma.

In partnership with: Celgene Ltd, Oncolytics Biotech Inc

Results

None as yet, recruitment ongoing.

What this means for patients

If this trial is successful, a second larger study could assess a new approach to treatment for relapsed/refractory myeloma using reovirus (Reolysin) plus a combination of lenalidomide and pomalidomide.


Learn more about our clinical trials via our trial finder page.

Find out where a specific drug is in the clinical trial pathway, by using our drug finder tool.

Help & Support: Speak to one of our trained and qualifed Myeloma Information Specialists or email us